Table 1.
Some U.S. Food and Drug Administration (FDA) approved antibiotics to combat methicillin-resistant Staphylococcus aureus (MRSA) infection [21].
| Antibiotics | Indications | Therapeutic Relevance | Resistant Strains Reported | Month/Year Approved | |
|---|---|---|---|---|---|
| For MRSA Infections | For Wound Infections | ||||
| Oritavancin | For the treatment of acute bacterial skin and skin structure infections | [22,23] | [22,23] | Low potential [24] | August 2014 |
| Sivextro | For the treatment of acute bacterial skin and skin structure infections | [25,26] | [27,28,29] | Low potential [25,30] | June 2014 |
| Dalvance | For the treatment of acute bacterial skin and skin structure infections | [31,32] | [31,32] | VanA vancomycin-resistant enterococci [33] | May 2014 |
| Teflaro | For the treatment of bacterial skin infections and bacterial pneumonia | [34,35,36] | [34,35,37] | A S. aureus [38] | October 2010 |
| Telavancin | For the treatment of complicated skin and skin structure infections | [39,40,41] | [40,42] | VanA vancomycin-resistant enterococci [33] | September 2009; June 2013 |
| Tigecycline | For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia | [39,43,44,45,46] | [45,47,48,49] | Staphylococcus spp. [50], an MRSA [51], an S. pneumoniae [52] | June 2005 |
| Daptomycin | For the treatment of complicated skin and skin structure infections | [39,43,45,53,54,55] | [45,53] | Dermabacter hominis [56], Staphylococcus spp. [45], a daptomycin non-susceptible S. aureus [57] | September 2003 |
| Linezolid | For the treatment of infections, including pneumonia, infections of the skin and infections caused by a resistant bacterium (Enterococcus faecium) | [39,43,45,58,59] | [45,60] | Vancomycin-resistant Enterococcus faecium. [61]; MRSA [62,63,64] | April 2000 |